FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Seagen's Free Cash Flow for the
three
months ended in Sep. 2023 was $-80 Mil. Seagen's Revenue for the
three
months ended in Sep. 2023 was $649 Mil. Therefore, Seagen's FCF Margin % for the quarter that ended in Sep. 2023 was -12.30%.
The historical rank and industry rank for Seagen's FCF Margin % or its related term are showing as below:
SGEN'
s FCF Margin % Range Over the Past 10 Years
Min: -43.53 Med: -28.46 Max: 35.58
Current: -30.48
During the past 13 years, the highest FCF Margin % of Seagen was 35.58%. The lowest was -43.53%. And the median was -28.46%.
SGEN's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -141.21
vs SGEN: -30.48
Seagen FCF Margin % Historical Data
The historical data trend for Seagen's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Seagen's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seagen's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Seagen's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Seagen's FCF Margin % falls into.
Seagen FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
Seagen's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seagen FCF Margin % Related Terms
Thank you for viewing the detailed overview of Seagen's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SGEN has been successfully added to your 